Compare Stocks

Date Range: 

 Trilogy International PartnersFutura MedicalAllergy TherapeuticsAvivagenN4 Pharma
SymbolTSE:TRLLON:FUMLON:AGYCVE:VIVLON:N4P
Price Information
Current PriceC$1.90GBX 39.20GBX 27C$0.39GBX 8.26
50-Day Moving AverageC$1.93GBX 44.06GBX 24.62C$0.41GBX 8.60
52-Week LowC$0.85GBX 12.11GBX 12.40C$0.33GBX 4.43
52-Week HighC$2.11GBX 84GBX 27.70C$0.78GBX 16
MarketRank™
Overall Score1.61.20.80.50.5
Analysis Score3.53.50.00.00.0
Community Score3.02.43.22.52.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.00.0
Earnings & Valuation Score0.00.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyN/AN/AN/A
Consensus Price TargetC$3.33GBX 102N/AN/AN/A
% Upside from Price Target75.44% upside160.20% upsideN/AN/AN/A
Trade Information
Market CapC$113.85 million£112.53 million£173.28 millionC$22.21 million£14.95 million
BetaN/AN/AN/AN/AN/A
Average Volume30,8671,777,560319,423110,0912,039,439
Sales & Book Value
Annual RevenueC$626.85 million£31,778.00£81.76 millionC$1.32 million£23,524.00
Price / Sales0.183,541.192.1216.80635.44
CashflowC$1.17 per shareGBX 0.38 per shareGBX 7.50 per shareC$0.07 per shareGBX 1.97 per share
Price / Cash1.63103.133.605.334.20
Book ValueC($1.60) per shareGBX 0.30 per shareGBX 9.20 per shareC($0.02) per shareGBX 2 per share
Price / Book-1.191.310.03-18.570.04
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($0.99)GBX (1)GBX 1C($0.12)GBX (1)
Trailing P/E RatioN/AN/A27.00N/AN/A
Forward P/E Ratio
P/E Growth39.78N/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A20.42%2,402.32%1.62%
Current Ratio1.16%2.06%4.23%0.97%22.63%
Quick Ratio0.77%2.03%3.61%0.77%22.54%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees1,66313600145
Shares Outstanding59.92 million287.07 million641.77 million56.96 million181.08 million
Next Earnings Date8/10/2021 (Estimated)9/14/2021 (Estimated)N/A9/1/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
N4 Pharma (LON:N4P) Trading 2.7% Higher N4 Pharma (LON:N4P) Trading 2.7% Higher
americanbankingnews.com - July 10 at 12:09 AM
Rurelec hit by delays in setting tariffs for Argentinian turbineRurelec hit by delays in setting tariffs for Argentinian turbine
proactiveinvestors.co.uk - May 20 at 5:08 PM
Fevertree shares bubble up after rise in off-trade sales during lockdownFevertree shares bubble up after rise in off-trade sales during lockdown
proactiveinvestors.co.uk - May 20 at 12:08 PM
Kanabo in demand after manufacturing agreement for cannabis productsKanabo in demand after manufacturing agreement for cannabis products
proactiveinvestors.co.uk - May 20 at 7:06 AM
N4 Pharma in demand after it unveils agreements with two major companiesN4 Pharma in demand after it unveils agreements with two major companies
proactiveinvestors.co.uk - May 20 at 7:06 AM
Were Not Very Worried About N4 Pharmas (LON:N4P) Cash Burn RateWe're Not Very Worried About N4 Pharma's (LON:N4P) Cash Burn Rate
finance.yahoo.com - March 2 at 7:33 AM
N4 Pharma losses widen as it works on commercialising NuvecN4 Pharma losses widen as it works on commercialising Nuvec
sharecast.com - February 24 at 12:37 PM
N4 Pharma books annual loss on higher R&D spendN4 Pharma books annual loss on higher R&D spend
shareprices.com - February 24 at 7:37 AM
N4 Pharma PLC - Final ResultsN4 Pharma PLC - Final Results
proactiveinvestors.co.uk - February 24 at 7:37 AM
N4 Pharma PLC - Notification of Intention to Grant PatentN4 Pharma PLC - Notification of Intention to Grant Patent
proactiveinvestors.co.uk - February 11 at 8:31 AM
N4 Pharma PLCN4 Pharma PLC
cnbc.com - January 23 at 11:11 PM
N4 Pharma PLC - Placing to raise £2 millionN4 Pharma PLC - Placing to raise £2 million
proactiveinvestors.co.uk - December 11 at 6:22 PM
N4 Pharma executes oversubscribed capital raiseN4 Pharma executes 'oversubscribed' capital raise
stockmarketwire.com - December 9 at 5:42 PM
N4 Pharma PLC - Second Price Monitoring ExtnN4 Pharma PLC - Second Price Monitoring Extn
proactiveinvestors.co.uk - November 27 at 12:50 AM
N4 Pharma PLC - Price Monitoring ExtensionN4 Pharma PLC - Price Monitoring Extension
proactiveinvestors.co.uk - November 27 at 12:50 AM
How Much Did N4 Pharmas (LON:N4P) CEO Pocket Last Year?How Much Did N4 Pharma's (LON:N4P) CEO Pocket Last Year?
finance.yahoo.com - November 23 at 12:00 PM
UBA Gross Earnings Hits N454.4Bn, Delivers NN90.4Bn PBT in Q3UBA Gross Earnings Hits N454.4Bn, Delivers NN90.4Bn PBT in Q3
msn.com - November 22 at 8:57 PM
IB Plc posts N4.6bn sales increase in Q3IB Plc posts N4.6bn sales increase in Q3
msn.com - November 22 at 8:57 PM
N4 Pharma PLC - SP Angel Research NoteN4 Pharma PLC - SP Angel Research Note
proactiveinvestors.co.uk - November 19 at 1:38 PM
Remote Monitored Sys - Second Price Monitoring ExtnRemote Monitored Sys - Second Price Monitoring Extn
proactiveinvestors.co.uk - November 13 at 11:19 PM
N4 Pharma Plc Regulatory NewsN4 Pharma Plc Regulatory News
lse.co.uk - November 5 at 11:07 PM
N4 Pharma realigns product towards COVID-19N4 Pharma realigns product towards COVID-19
stockmarketwire.com - September 17 at 8:22 AM
Bolsa de Londres: Índice FTSE 100 abre estável nesta segunda-feira, 14 de setembro de 2020Bolsa de Londres: Índice FTSE 100 abre estável nesta segunda-feira, 14 de setembro de 2020
br.advfn.com - September 15 at 12:28 AM
N4 Pharma get nul points from coronavirus antibody trialN4 Pharma get nul points from coronavirus antibody trial
proactiveinvestors.co.uk - September 14 at 9:26 AM
N4 Pharma to conduct new Covid-19 research after negative study resultN4 Pharma to conduct new Covid-19 research after negative study result
stockmarketwire.com - September 14 at 4:25 AM
DateCompanyBrokerageAction
7/14/2021Trilogy International PartnersRoyal Bank of Canada
Boost Price Target
6/3/2021Futura MedicalLiberum Capital
Boost Price Target
5/13/2021Trilogy International PartnersScotiabank
Boost Price Target
5/13/2021Trilogy International PartnersTD Securities
Boost Price Target
4/14/2021Futura MedicalLiberum Capital
Reiterated Rating
3/30/2021Trilogy International PartnersTD Securities
Boost Price Target
3/30/2021Trilogy International PartnersRoyal Bank of Canada
Reiterated Rating
12/10/2020Trilogy International PartnersTD Securities
Boost Price Target
11/12/2020Trilogy International PartnersTD Securities
Boost Price Target
7/16/2020Trilogy International PartnersTD Securities
Boost Price Target
7/15/2020Allergy TherapeuticsFinnCap
Reiterated Rating
7/14/2020Futura MedicalLiberum Capital
Reiterated Rating
7/9/2020Allergy TherapeuticsFinnCap
Reiterated Rating
6/24/2020Futura MedicalLiberum Capital
Reiterated Rating
6/24/2020Allergy TherapeuticsFinnCap
Reiterated Rating
5/20/2020Trilogy International PartnersTD Securities
Upgrade
5/18/2020Futura MedicalLiberum Capital
Reiterated Rating
4/20/2020Futura MedicalLiberum Capital
Reiterated Rating
4/1/2020Futura MedicalLiberum Capital
Reiterated Rating
3/26/2020Trilogy International PartnersScotiabank
Lower Price Target
3/26/2020Trilogy International PartnersRoyal Bank of Canada
Lower Price Target
3/23/2020Trilogy International PartnersTD Securities
Downgrade
3/18/2020Futura MedicalLiberum Capital
Reiterated Rating
3/4/2020Allergy TherapeuticsFinnCap
Reiterated Rating
2/13/2020Futura MedicalLiberum Capital
Reiterated Rating
2/3/2020Allergy TherapeuticsFinnCap
Reiterated Rating
1/16/2020Allergy TherapeuticsFinnCap
Reiterated Rating
12/23/2019Futura MedicalLiberum Capital
Reiterated Rating
12/10/2019Futura MedicalLiberum Capital
Reiterated Rating
12/4/2019Trilogy International PartnersTD Securities
Lower Price Target
11/28/2019Futura MedicalLiberum Capital
Reiterated Rating
11/28/2019Allergy TherapeuticsFinnCap
Reiterated Rating
11/15/2019Futura MedicalLiberum Capital
Reiterated Rating
9/30/2019Trilogy International PartnersRoyal Bank of Canada
Upgrade
9/25/2019Allergy TherapeuticsFinnCap
Reiterated Rating
9/10/2019Futura MedicalLiberum Capital
Reiterated Rating
7/11/2019Allergy TherapeuticsFinnCap
Reiterated Rating
6/28/2019Allergy TherapeuticsFinnCap
Reiterated Rating
6/17/2019Futura MedicalLiberum Capital
Initiated Coverage
4/29/2019Allergy TherapeuticsFinnCap
Reiterated Rating
4/1/2019Trilogy International PartnersRoyal Bank of Canada
Boost Price Target
3/22/2019Allergy TherapeuticsFinnCap
Lower Price Target
3/18/2019Allergy TherapeuticsNumis Securities
Reiterated Rating
3/6/2019Allergy TherapeuticsNumis Securities
Reiterated Rating
3/6/2019Allergy TherapeuticsFinnCap
Reiterated Rating
2/20/2019Trilogy International PartnersTD Securities
Boost Price Target
1/16/2019Allergy TherapeuticsFinnCap
Reiterated Rating
11/21/2018Trilogy International PartnersTD Securities
Upgrade
11/13/2018Trilogy International PartnersRoyal Bank of Canada
Downgrade
11/9/2018Trilogy International PartnersTD Securities
Lower Price Target
10/16/2018Trilogy International PartnersTD Securities
Lower Price Target
9/27/2018Allergy TherapeuticsFinnCap
Reiterated Rating
9/26/2018Allergy TherapeuticsNumis Securities
Reiterated Rating
(Data available from 7/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.